ProCE Banner Series

APPlexus GI: Clinic-Ready Insights From the Top Abstracts Presented at the 2024 Gastrointestinal Cancers Symposium

APPlexus GI is an initiative designed to address educational needs specific to advanced practice providers who care for patients with gastrointestinal cancers. This webinar will navigate insights from the 2024 ASCO Gastrointestinal Cancers Symposium and will deliver innovative, real-time education to nurse practitioners and physician associates worldwide. Our mission is to bridge knowledge gaps, untangle controversies, and spotlight pivotal abstracts from ASCO GI 2024 in a digestible and engaging format.

  AAPA
  | ANCC
Who Should Attend

This program is intended for nurse practitioners, physician associates, and other healthcare professionals who care for patients with gastrointestinal cancers.

All Events

APPlexus GI: Clinic-Ready Insights From the Top Abstracts Presented at the 2024 Gastrointestinal Cancers Symposium

Upcoming Events

March

09

2024

8:00 AM - 12:15 PM Eastern Time (ET)

Virtual

Faculty

ProCE Banner Faculty
Katie Alexander, MS, AGACNP-BC, RN

Lead Advanced Practice Provider
Oncology
Zangmeister Cancer Center
Columbus, OH

ProCE Banner Faculty
Nina N. Grenon, DNP, AOCN

Adult-Gerontology Nurse Practitioner
Center for Gastrointestinal Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts

ProCE Banner Faculty
Thomas B. Karasic, MD

Assistant Professor of Medicine
Physician Leader, Developmental Therapeutics
Division of Hematology-Oncology
University of Pennsylvania
Philadelphia, Pennsylvania

ProCE Banner Faculty
Gabriel Schwartz, MSN, FNP-BC, AOCNP

Lead Nurse Practitioner
GI Medical Oncology
UCSF Medical Center
San Francisco, CA

Topics

Time (ET)

8:00 AM - 9:00 AM: Nonaccredited Presentation Theater: LONSURF® + bevacizumab for the Treatment of 3L Metastatic Colorectal Cancer Sponsored by Taiho Oncology 

9:00 AM - 10:05 AM: Welcome & A Review of Key CRC Studies From the 2024 ASCO Gastrointestinal Cancers Symposium

10:05 AM - 11:05 AM: Nonaccredited Presentation Theater: PEMAZYRE® (pemigatinib): The First FDA-Approved Treatment for Adults With Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with an FGFR2 Fusion or Rearrangement as Detected by an FDA-Approved Test Sponsored by Incyte Corporation 

11:05 AM - 12:15 PM: A Review of Key Hepatobiliary Studies From the 2024 ASCO Gastrointestinal Cancers Symposium & Qualitative Assessment of and Commitment to Practice Change

12:15 PM: Adjournment

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.

CME/CE Info

Goal Statement
The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with GI Cancers.

Target Audience
This program is intended for NPs, PAs, and other healthcare professionals who care for patients with gastrointestinal cancers.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Integrate recent clinical data to tailor and enhance treatment strategies for patients diagnosed with gastrointestinal cancers
  • Assess the implications and potential of emerging agents and therapeutic innovations in managing patients with gastrointestinal cancers
  • Evaluate the potential impact of contemporary trial outcomes on shaping future treatment paradigms for patients with gastrointestinal cancers

Accreditation

In support of improving patient care, Partners for Advancing Clinical Education (PACE) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. 

Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 2.0 contact hours, including 2.0 hours of pharmacotherapy credit.

- A Review of Key CRC Studies: 1.0
- A Review of Key Hepatobiliary Studies: 1.0

Physician Associate Continuing Medical Education

Partners for Advancing Clinical Education (PACE) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 2.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

- A Review of Key CRC Studies: 1.0
- A Review of Key Hepatobiliary Studies: 1.0

IPCE Credit Designation

This activity was planned by and for the healthcare team, and learners will receive 2.00 Interprofessional Continuing Education (IPCE) credits for learning and change.

- A Review of Key CRC Studies: 1.0
- A Review of Key Hepatobiliary Studies: 1.0

Disclosure of Conflicts of Interest
PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are mitigated according to PACE policies.

Acknowledgement

Provided by Partners for Advancing Clinical Education (PACE) in partnership with Practicing Clinicians Exchange, LLC and Clinical Care Options, LLC